MDM2 Antagonists Counteract Drug-Induced DNA Damage
Anna E. Vilgelm(The Ohio State University), Ann Richmond(Monroe Carell Jr. Children's Hospital), Priscilla Cobb(Vanderbilt University), Mark C. Kelley(Vanderbilt University), Douglas B. Johnson(Vanderbilt University Medical Center), Brandon Vara(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeffrey N. Johnston(Vanderbilt University), Brian Higgins(La Roche College), Sheau‐Chiann Chen(Vanderbilt University Medical Center), David K. Flaherty(Vanderbilt University Medical Center), Nabil Saleh(Ain Shams University), Dayanidhi Raman(University of Toledo), Kiran L Malikayil(Meharry Medical College), Christopher Andrew Johnson(Vanderbilt University), Gregory D. Ayers(Vanderbilt University)
Cited by 14
Related Papers
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k